20 Aug Topical Ivermectin for Rosacea: What the Phase 3 Evidence Actually Shows
Ivermectin is better known as an oral antiparasitic, so its arrival as a first-line topical treatment for papulopustular rosacea took some clinicians by surprise. The evidence base behind that shift is unusually clean for dermatology: a large head-to-head trial against an established comparator, a controlled extension measuring relapse, and long-term safety data against a second active agent.
Why Ivermectin Was Tried at All
Two rationales converge. Demodex mite density is elevated in rosacea skin, and ivermectin is directly active against Demodex. Separately, ivermectin has anti-inflammatory activity independent of its antiparasitic effect. Papulopustular rosacea involves both an inflammatory component and a mite burden, so a single agent acting on both was a reasonable hypothesis rather than a repurposing accident.
The Head-to-Head Result
The ATTRACT study randomised 962 patients with moderate to severe papulopustular rosacea to ivermectin 1% cream once daily or metronidazole 0.75% cream twice daily over 16 weeks, with investigator blinding. At week 16, ivermectin produced an 83.0% reduction in inflammatory lesions from baseline against 73.7% for metronidazole. On Investigator Global Assessment, 84.9% of the ivermectin group were rated clear or almost clear against 75.4% of the metronidazole group. Both differences reached statistical significance at P below 0.001, and separation between the arms was already visible at the first assessment at week 3.
Two features of the design are worth holding onto when reading those numbers. Ivermectin achieved the superior result on once-daily application against a twice-daily comparator, which matters for adherence in a chronic condition. Local tolerability also favoured ivermectin, and adverse event rates were comparable between arms.
What Happened After Treatment Stopped
The 36-week extension of ATTRACT followed patients who had responded, then withdrew treatment. Median time to first relapse was 115 days for patients initially treated with ivermectin against 85 days for those treated with metronidazole. Relapse rates by the end of the observation period were 62.7% and 68.4% respectively, and median treatment-free days were 196 against 169.5.
That is a real difference, but it deserves a proportionate reading. A month of additional remission is clinically useful. It is not remission. Roughly two thirds of responders in both arms relapsed within the observation window, which is the more important number for setting patient expectations.
Long-Term Safety
Two 40-week investigator-blinded trials compared ivermectin 1% cream against azelaic acid 15% gel and found the safety profile favourable over extended use. For a condition treated for years rather than weeks, that duration of controlled follow-up carries more weight than a 16-week efficacy figure on its own.
Where It Sits in Treatment Sequencing
Rosacea is not one disease behaving consistently, and the trial population matters when translating these results. The evidence supports topical ivermectin as a first-line option for the inflammatory papules and pustules that define the papulopustular subtype. It says nothing useful about persistent central erythema, flushing, or visible vessels, which respond to a different set of interventions and frequently persist after the papules clear.
That distinction is where patient dissatisfaction usually originates. A patient whose lesion count falls by more than eighty percent but whose face is still red will describe the treatment as having failed. Setting the expectation before starting — that this agent addresses one component of the condition and not the whole presentation — does more for perceived outcome than any adjustment to the regimen itself.
The Honest Limitations
- The comparator was metronidazole 0.75%, not the full range of alternatives a clinician might reach for.
- Enrolment was restricted to moderate to severe papulopustular disease, so the numbers do not transfer to erythematotelangiectatic rosacea, where the mechanism is different and the response is generally poorer.
- Investigator blinding is not patient blinding, and dosing frequency differed between the arms.
- Cost is not a trial endpoint but decides real-world use, and the branded topical is priced well above generic metronidazole in most markets.
The Practical Read
For moderate to severe papulopustular rosacea, topical ivermectin has the strongest comparative dataset currently available, and the once-daily schedule is a genuine advantage in a condition that requires indefinite treatment. It is not curative, relapse after withdrawal is the expected outcome rather than the exception, and the flushing and telangiectasia components of rosacea will need addressing separately.
Primary sources: The ATTRACT trial is indexed on PubMed as PMID 25228137 and the relapse extension as PMID 26691278. A patient-facing summary of the same evidence is maintained by SafeRxPills.
About the Author: Lokesh Maurya, B.Pharm, M.Pharm, works on clinical content and medicine information review at SafeRxPills, and writes on dermatological therapeutics, antiparasitic pharmacology, and generic medicine access.
For a broader overview of how topical ivermectin (Soolantra) compares with combination oral and topical regimens for severe papulopustular rosacea, see this MedicalResearch.com interview on the ANSWER study findings on Oracea and Soolantra for severe inflammatory rosacea.
Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on August 20, 2026 by Marie Benz MD FAAD